Corient Private Wealth LP Invests $1.26 Million in Chemed Corporation $CHE

Key Points

• Corient Private Wealth purchased 2,704 Chemed shares worth approximately $1.26 million during the second quarter. Institutional investors collectively own 95.85% of the company.
• Chemed exceeded quarterly expectations, reporting $6.06 in earnings per share and $673.25 million in revenue, while revenue increased 8.8% year over year. The company set fiscal 2026 guidance at $25.00–$25.75 EPS.
• Chemed raised its quarterly dividend from $0.60 to $0.70 per share, equivalent to an annualized $2.80 dividend and a 0.5% yield. Analysts maintain a consensus “Hold” rating with an average price target of $530.75.

Corient Private Wealth LP purchased a new stake in shares of Chemed Corporation (NYSE:CHE - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 2,704 shares of the company's stock, valued at approximately $1,259,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Geneos Wealth Management Inc. boosted its stake in Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company's stock valued at $61,000 after purchasing an additional 76 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Chemed by 67.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company's stock valued at $5,534,000 after purchasing an additional 4,560 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Chemed during the second quarter valued at $579,000. Brown Advisory Inc. increased its holdings in Chemed by 36.9% in the 2nd quarter. Brown Advisory Inc. now owns 549 shares of the company's stock worth $267,000 after buying an additional 148 shares in the last quarter. Finally, Cerity Partners LLC increased its holdings in Chemed by 237.7% in the 2nd quarter. Cerity Partners LLC now owns 4,451 shares of the company's stock worth $2,165,000 after buying an additional 3,133 shares in the last quarter. Institutional investors own 95.85% of the company's stock.

Insider Buying and Selling

In related news, Director Patrick Grace sold 190 shares of Chemed stock in a transaction on Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the transaction, the director directly owned 3,533 shares in the company, valued at approximately $1,879,556. The trade was a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin McNamara sold 2,000 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $539.51, for a total value of $1,079,020.00. Following the sale, the chief executive officer directly owned 70,418 shares of the company's stock, valued at $37,991,215.18. This represents a 2.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,537 shares of company stock valued at $3,406,014 in the last 90 days. 3.33% of the stock is owned by company insiders.

Chemed Price Performance

Shares of NYSE:CHE opened at $520.82 on Friday. The company has a quick ratio of 0.89, a current ratio of 0.91 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $6.81 billion, a PE ratio of 26.16, a price-to-earnings-growth ratio of 1.99 and a beta of 0.51. The firm's 50 day moving average price is $516.70 and its 200-day moving average price is $451.82. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $557.00.

Chemed (NYSE:CHE - Get Free Report) last announced its earnings results on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating analysts' consensus estimates of $5.60 by $0.46. The business had revenue of $673.25 million during the quarter, compared to analysts' expectations of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm's revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the company earned $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Equities research analysts expect that Chemed Corporation will post 23.18 EPS for the current year.

Chemed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Monday, August 17th were issued a $0.70 dividend. The ex-dividend date of this dividend was Monday, August 17th. This represents a $2.80 dividend on an annualized basis and a yield of 0.5%. This is an increase from Chemed's previous quarterly dividend of $0.60. Chemed's payout ratio is 14.06%.

Analysts Set New Price Targets

Several research firms have issued reports on CHE. Wall Street Zen upgraded shares of Chemed from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 1st. Weiss Ratings raised shares of Chemed from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, July 17th. Oppenheimer increased their price objective on shares of Chemed from $500.00 to $590.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. Royal Bank Of Canada raised their target price on shares of Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a report on Thursday, July 30th. Finally, Bank of America reiterated a "neutral" rating on shares of Chemed in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $530.75.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source